分子特征将BAP1改变型脑膜瘤定义为一种Polycomb抑制复合物靶基因失调的独特中枢神经系统肿瘤
研究以6例已知BAP1改变的脑膜瘤为发现集,经全基因组DNA甲基化谱分析并结合11151例参考脑膜瘤,识别出一个含42例的独特分子簇;整合分析显示该类肿瘤以3p21反复缺失和多种BAP1失活改变为特征,中位无进展生存21个月(95%CI:12-NA),2年总生存率79%(95%CI:60%-100%),并伴PRC靶基因上调与Polycomb信号失调。
要点
- BAP1改变型脑膜瘤构成独特分子簇(n=42),以3p21反复缺失和BAP1失活改变为特征。
- 横纹肌样形态仅见于部分病例,不应作为分级标准。
- 中位无进展生存21个月(95%CI:12-NA),2年总生存率79%(95%CI:60%-100%)。
核心结论
- BAP1改变型脑膜瘤是一种独特且侵袭性的中枢神经系统肿瘤亚型,与PRC失调和3p染色体反复缺失相关,支持命名为「脑膜瘤,BAP1改变型」。
研究设计与样本
- 以6例已知BAP1改变的脑膜瘤为发现集,对样本行全基因组DNA甲基化谱分析,并与11151例参考脑膜瘤比较,采用无监督可视化方法识别出含42例的独特分子簇。
- 对上述肿瘤进一步行DNA/RNA测序、组织病理学检查及临床数据回顾性复习,并与参考脑膜瘤队列比较。
主要发现
- BAP1改变型脑膜瘤以3p21染色体反复缺失为特征,并由多种BAP1失活改变驱动。
- 横纹肌样形态见于部分病例但并非全部,不应作为分级标准。
- 无进展生存分析显示中位无进展生存21个月(95%CI:12-NA),2年总生存率79%(95%CI:60%-100%)。
- 基因表达谱显示PRC靶基因上调、Polycomb信号失调,以及多个细胞和生长因子通路表达升高。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Meningiomas are the most common primary intracranial neoplasms, with highly variable patient outcomes. While most meningiomas are benign, a significant subset recurs postoperatively, presenting substantial treatment challenges. BAP1 gene inactivation has been suggested as a marker for aggressive meningiomas, although its precise molecular and clinical roles remain poorly understood. METHODS: To comprehensively investigate BAP1-altered meningiomas, we used six meningiomas with known BAP1 alterations as a discovery set. Genome-wide DNA methylation profiling of these samples, along 11 151 reference meningiomas, identified a distinct molecular cluster (n = 42) using unsupervised visualization approaches. These tumors were further characterized by DNA/RNA sequencing, histopathological examination, and a retrospective review of clinical data, compared to reference meningioma cohorts, providing a thorough characterization of this rare tumor subtype. RESULTS: Our integrative analysis revealed BAP1-altered meningiomas as a distinct CNS tumor subtype, characterized by recurrent loss of chromosome 3p21 and driven by various BAP1-inactivating alterations. Although rhabdoid morphology is present in some cases, it is not exclusive and should not be used as a grading criterion. Progression-free survival analysis showed a median of 21 months (95% CI: 12-NA), with a 2-year overall survival rate of 79% (95% CI: 60%-100%), highlighting the aggressive nature of these tumors. Gene expression profiling revealed upregulation of PRC target genes, dysregulated Polycomb signaling, and elevated expression in several cellular and growth factor pathways. CONCLUSIONS: BAP1-altered meningiomas represent a distinct and aggressive CNS tumor subtype associated with PRC dysregulation and recurrent 3p chromosome loss. These findings support the designation "meningioma, BAP1-altered."
引用
- Sievers P, Arora S, Hielscher T, et al. Molecular signatures define BAP1-altered meningioma as a distinct CNS tumor with deregulation of Polycomb repressive complex target genes. Neuro Oncol. 2025. PMID: 40249111. doi:10.1093/neuonc/noaf105
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。